Effectiveness of Immune Checkpoint Inhibitor with Anti-PD-1 Monotherapy or in Combination with Ipilimumab in Younger versus Older Adults with Advanced Melanoma
<b>Background</b>: The majority of melanoma is diagnosed in individuals between 55 and 84 years old. Current data varied in reporting differences in survival outcomes amongst different age groups. <b>Methods:</b> A retrospective, multi-center, provincial cohort database was u...
Main Authors: | Taylor E. Woo, Igor Stukalin, Philip Q. Ding, Siddhartha Goutam, Michael Sander, Benjamin Ewanchuk, Winson Y. Cheung, Daniel Y. C. Heng, Tina Cheng |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-09-01
|
Series: | Current Oncology |
Subjects: | |
Online Access: | https://www.mdpi.com/1718-7729/30/10/646 |
Similar Items
-
Outcome of Elective Checkpoint Inhibitor Discontinuation in Patients with Metastatic Melanoma Who Achieved a Complete Remission: Real-World Data
by: Leanne Perez, et al.
Published: (2022-05-01) -
Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma
by: Samuel Rosner, et al.
Published: (2018-03-01) -
Cutaneous Melanoma versus Vulvovaginal Melanoma—Risk Factors, Pathogenesis and Comparison of Immunotherapy Efficacy
by: Anna Lorenz, et al.
Published: (2022-10-01) -
Immunotherapy and Cannabis: A Harmful Drug Interaction or Reefer Madness?
by: Brian J. Piper, et al.
Published: (2024-03-01) -
Lack of Influence of Non-Overlapping Mutations in <i>BRAF</i>, <i>NRAS</i>, or <i>NF1</i> on 12-Month Best Objective Response and Long-Term Survival after Checkpoint Inhibitor-Based Treatment for Metastatic Melanoma
by: Alyssa Panning, et al.
Published: (2023-07-01)